Skip to content
Screener

MoonLake Immunotherapeutics MLTX Q4 2024 Annual earnings

Reported February 26, 2025 · Before market open

Revenue$101.9K
EPS-$0.72Miss by $0.19
EPS estimate-$0.53

Next report

Aug 11, 2026 (In 2 days)
EPS estimate-$0.92

Financials

Q4 2024

Income statement

See full
Operating income-$49.6M-230%
Net income-$45.6M-513%
EPS (diluted)-$0.72-620%

Balance sheet

See full
Cash & equivalents$180.4M-60.0%
Total debt$2.8M-23.5%
Total equity$446.8M-9.9%
Total assets$477.9M-9.2%

Cash flow

See full
Operating cash flow-$48.5M-293%
CapEx$176.0K-38.0%
Free cash flow-$48.6M-285%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$3.41B-5.6%
Enterprise value$3.24B+2.1%

Returns & leverage

See full
Return on equity-25.2%+251pp
Debt / equity0×0.0×
Current ratio21.1×-30.5×

FAQ

When did MoonLake Immunotherapeutics report Q4 2024 earnings?
MoonLake Immunotherapeutics (MLTX) reported Q4 2024 earnings on February 26, 2025 before market open.
What were MoonLake Immunotherapeutics's Q4 2024 revenue and EPS?
MoonLake Immunotherapeutics reported revenue of $101.9K and eps of $-0.72 for Q4 2024.
Did MoonLake Immunotherapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.53 by $0.19.
Where can I find MoonLake Immunotherapeutics's Q4 2024 SEC filings?
You can read the 8-K earnings release (0001821586-25-000004) and the 10-K periodic report (0001821586-25-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.